Skip to main content
    D

    Dianthus Therapeutics Inc. (DNTH)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $89.55
    -2.26 (-2.46%)

    Market Cap: $5.17B

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Dianthus Therapeutics Inc. (DNTH) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Dianthus Therapeutics reported revenue of $2.04M for the fiscal year ended Dec 31, 2025, down 67.3% from the year before. That year, net income was -$162.34M with a net margin of -7973.3%, operating cash flow was -$129.06M and free cash flow was -$129.27M. The quarter ended Sep 30, 2026 had revenue of $1.21M and net income of -$46.64M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$2.04M-67.3%100.0%-8739.3%-7973.3%
    Dec 2024$6.24M+120.6%100.0%-1633.7%-1362.8%
    Dec 2023$2.83M-56.0%100.0%-1704.7%-1541.2%
    Dec 2022$6.42MN/A100.0%-462.9%-443.8%
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$2.04M$6.24M$2.83M$6.42M$0$0$0$0$0$0
    Gross profit$2.04M$6.24M$2.83M$6.42M$0$0$0$0$0$0
    Research and development$145.64M$83.11M$32.84M$29.38M$46.77M$50.62M$59.21M$41.34M$27.90M$5.78M
    Operating income-$177.93M-$101.86M-$48.17M-$29.70M-$74.69M-$78.70M-$82.97M-$59.96M-$35.73M-$9.27M
    Net income-$162.34M-$84.97M-$43.55M-$28.48M-$71.14M-$74.94M-$76.77M-$57.52M-$35.49M-$9.43M
    EBITDAN/AN/AN/AN/A-$72.67M-$76.55M-$82.14M-$59.28M-$35.35M-$9.26M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.21M$761.00K$0$873.00K$0$0$1.16M$1.33M$2.17M$1.86M$874.00K$457.00K
    Gross profit$1.21M$761.00K$0$873.00K$0$0$1.16M$1.33M$2.17M$1.86M$874.00K$457.00K
    Operating income-$58.47M-$61.48M-$46.53M-$69.54M-$40.29M-$34.93M-$33.18M-$31.92M-$29.90M-$22.20M-$17.84M-$12.96M
    Net income-$46.64M-$50.22M-$40.83M-$64.43M-$36.77M-$31.63M-$29.51M-$28.44M-$25.17M-$17.61M-$13.75M-$10.56M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $367.00K by $50.72M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$530.92M$374.01M$179.41M$83.11M$189.93M$161.62M$161.51M$157.31M$54.46M$11.34M
    Current assets$409.44M$280.90M$177.45M$82.03M$180.69M$151.53M$149.84M$145.32M$52.50M$10.83M
    Cash and equivalents$51.09M$22.79M$132.32M$15.37M$131.65M$58.15M$65.07M$58.34M$51.40M$4.54M
    Total liabilities$37.52M$21.53M$10.54M$9.45M$17.26M$17.71M$20.32M$11.66M$4.14M$2.30M
    Short-term debt$367.00K$320.00K$417.00K$350.00KN/AN/AN/AN/AN/AN/A
    Shareholder equity$493.40M$352.48M$168.87M-$44.37M$172.67M$143.91M$141.19M$145.65M-$42.12M$9.04M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.28B$1.21B$1.25B$530.92M$577.45M$326.08M$348.58M$374.01M$354.25M$368.96M$382.46M$179.41M
    Total liabilities$34.82M$41.25M$45.57M$37.52M$30.99M$23.00M$19.97M$21.53M$16.35M$10.74M$9.78M$10.54M
    Cash and equivalents$55.69M$110.55M$627.67M$51.09M$55.98M$13.24M$10.12M$22.79M$33.67M$314.17M$329.72M$132.32M
    Shareholder equity$1.24B$1.17B$1.20B$493.40M$546.45M$303.08M$328.61M$352.48M$337.90M$358.22M$372.69M$168.87M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$129.06M-$78.18M-$36.86M-$29.07M-$59.53M-$64.02M-$57.10M-$41.89M-$22.26M-$6.53M
    Capital expenditures$213.00K$105.00K$110.00K$139.00K$1.26M$400.00K$3.06M$7.67M$2.20M$139.00K
    Free cash flow-$129.27M-$78.28M-$36.97M-$29.21M-$60.80M-$64.42M-$60.16M-$49.56M-$24.46M-$6.67M
    Share repurchasesN/AN/AN/A$0$303.00K$297.00K$598.00K$3.09M$0$0
    Investing cash flow-$122.83M-$286.81M$20.25M-$59.82M$43.43M-$10.63M$1.53M-$91.70M-$2.20M-$139.00K
    Financing cash flow$280.13M$255.62M$133.57M$96.68M$89.60M$67.74M$62.30M$142.15M$71.49M$10.71M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$50.33M-$48.98M-$28.86M-$46.98M-$30.55M-$23.89M-$27.63M-$27.44M-$21.27M-$14.53M-$14.94M-$11.85M
    Capital expenditures$368.00K$181.00K$10.00K$138.00K$5.00K$46.00K$24.00K$31.00K$25.00K$17.00K$32.00K$10.00K
    Free cash flow-$50.70M-$49.16M-$28.87M-$47.12M-$30.56M-$23.94M-$27.65M-$27.48M-$21.29M-$14.54M-$14.97M-$11.86M
    Last 12 quarters

    Frequently Asked Questions About DNTH

    What is Dianthus Therapeutics' annual revenue?

    Dianthus Therapeutics reported revenue of $2.04M for the fiscal year ended Dec 31, 2025.

    How fast is Dianthus Therapeutics' revenue growing?

    Revenue was down 67.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -31.8%.

    Is Dianthus Therapeutics profitable?

    No. Dianthus Therapeutics reported net income of -$162.34M for the fiscal year ended Dec 31, 2025, with a net margin of -7973.3%.

    How much free cash flow does DNTH generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$129.06M minus capital expenditures of $213.00K produced free cash flow of -$129.27M.

    How much debt does Dianthus Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $367.00K and cash and equivalents of $51.09M.